AMS Capital’s AtriCure ATRC Stock Holding History

AMS Capital’s Portfolio ATRC Stock Details ATRC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-20,687	Closed	-$725K	–	19
2018 Q3	$725K	Buy	+20,687	New	+$655K	0.6%	33

Other funds holding ATRC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AMS Capital's ATRC Position: Q4 2018 in Review

AMS Capital sold out of AtriCure (ATRC) in Q4 2018, closing a stake of 20,687 shares — an estimated $725K sold.

AMS Capital first reported a position in ATRC in Q3 2018 and held it in 1 quarter. The position peaked at $725K in Q3 2018. 147 funds tracked by Wall St. Rank hold ATRC as of Q4 2018.

AMS Capital reported no remaining AtriCure position as of Q4 2018 after selling out during the quarter.
AMS Capital sold 20,687 AtriCure shares in Q4 2018, an estimated $725K.
AMS Capital first reported a position in AtriCure in Q3 2018 and held it in 1 quarter.
AMS Capital's AtriCure position peaked at $725K in Q3 2018.
147 funds tracked by Wall St. Rank held AtriCure as of Q4 2018.

Based on AMS Capital's 13F filing for Q4 2018, filed 29 Jan 2019.